[ We help ideas take flight ]

Subscribe to our newsletter !

Univalor – Your Guide

You’re an entrepreneur with big plans for your business. To ensure your growth, you need to keep innovating, find ways to make your mark and increase your competitiveness. At Univalor, we work on the front lines to identify the innovations that can help your business enrich its line of products or services or improve its productivity. We have over 400 protected technologies, ready to be commercially exploited in the form of new products, services or processes.

Since 2001, Univalor is commercializing scientific findings and technological innovations emanating from some 2600 researchers of the Université de Montréal and its affiliated health centres, Polytechnique Montréal and HEC Montréal in the areas of pure and applied sciences, engineering, information technology, management sciences, life sciences and human health.

By creating linkages between the university and the business community, Univalor helps make businesses more competitive, generate revenue for research and, most importantly, to enrich society.

In business with Univalor

Technology transfer

Have you identified a technology that's right for your business? Univalor can develop a customized solution by determining the best form of transfer (licence, option, transfer of knowledge or material).

Partnership opportunities

Do you want to establish ties for research and development? We know all the players in the research network of Université de Montréal and affiliated institutions. We are positioned to facilitate exchanges and create productive partnerships between industry and researchers.

Create a spin-off company

Are you ready to start a business to commercialize one of your technologies? Univalor gets actively involved in starting up spin-off businesses by bringing together visionaries and identifying sources of financing to support it during the first phase of development. Here are the spin-off companies created by Univalor

Support researchers

Univalor represents some 2600 researchers of the Université de Montréal and its affiliated health centres, Polytechnique Montréal and HEC Montréal in the areas of pure and applied sciences, engineering, information technology, management sciences, life sciences and human health. It accompanies them in the marketing of the technological innovations or the scientific discoveries.


With over 2000 products from 1500 researchers, eValorix.com is the perfect place to distribute your products created from public research. eValorix.com is a platform for distributing digital and physical products by secure transaction and measuring the impact of this distribution. Visit the eValorix.com web site Become an eValorix partner to distribute your innovations

What you need to know about tech transfer

The development of research is based on the set of activities aimed at increasing the value of the results of research and develop knowledge. The valuation is not limited only to the commercial exploitation of these results, it also relies on the dissemination and exchange of knowledge in all areas of knowledge development.

Technology Transfer, meanwhile, is a movement transmission and reception of knowledge and technological know-how and organizational partners, to increase the expertise and knowledge of at least one partner and to strengthen its competitiveness.

Technology transfer of university research generates economic and social benefits for researchers, institutions represented by Univalor, and industry partners.

Univalor at the heart of the ecosystem

Working with nine member-institutions, Univalor commercializes a world of discoveries. So far, our professionals have identified and evaluated commercially promising innovations resulting from university research. Univalor is behind many partnership agreements between universities and the business world.

A great number of technology and social innovations have been transferred to industry in the form of licences, licence options, material or knowledge transfer agreements and research contracts. We have also helped start many spin-off companies, some of which are now known around the world. These businesses have created some 875 direct and indirect jobs in Québec.

Technology Showcase

Univalor’s portfolio has more than 200 available technologies. To learn more about them, contact the team.


With backgrounds in life sciences, engineering, finance and law, our team members work toward a single goal: to achieve the full value of university discoveries and innovations. The diversity and depth of our expertise ensures the quality of our services and allows us to establish effective, productive exchanges between researchers, representatives of member institutions, and industry partners.

To reach us, use the form below or call us at the phone number shown.


Office of Luc Paquet, President & CEO:
Christine Gariépy
Executive Assistant
514 340-8504

Legal and Corporate Affairs

Marie-Josée Lapointe, LL. B.
Vice-president, Legal and Corporate Affairs
514 340-8507

Myriam Pigeon
Legal Assistant, Business Law and Intellectual Property
514 340-8525

David Siméon , LL. B.
Legal Counsel
514 340-8506

Business Development

Anne-Marie Alarco, Ph.D.
Project Manager, Life Sciences
514 340-8522

Andréa Arias, Ph.D.
Project Manager, Sciences and Engineering
514 340-8510

Mounia Arkoun, Ph. D.
Project Manager, Sustainable Development
514 340-8524

Clermont Beaulieu, Ph.D., MBA
Consultant, Business Development
514 340-8518

Benoit Doré, Ph.D.
Project Manager, Life Sciences
514 340-8521

Lotfi Kesraoui, M.Sc. A., MBA
Project Manager, Sciences and Engineering
514 340-8519

Jean-Guy Némorin, Ph.D.
Project Manager, Life Sciences
514 340-8509

Julia Rouchet
Senior Advisor, Project Valorization, TransMedTech/Univalor
514 340-0663

Jean-Claude Sabourin, M.Sc.
Senior Advisor, Analysis, Strategy and Business Development
514 340-8503dréa

Finance and Administration

To reach the Department of Finance and Administration: 514 340-8515

Johanne Dépatie, CPA CGA
Director, Finance and Administration

Chantal Richer
Accounting Technician

Christiane Beauregard
Accounting Technician


Nathalie Pentier, M.A.
Communications and Social Media Agent
514 340-8508


Patrick Tremblay is a biopharmaceutical and investment executive with broad expertise in R&D and business development. He joined the team of Caprion Proteome in 2011 as Senior Vice-President, Corporate Development and Diagnostics. He is leading the corporate strategies and the development of innovative diagnostics based on proteomic discoveries made at Caprion for indications such as cancer, infection and metabolic diseases.

Prior to joining Caprion, Patrick has worked with Pappas Ventures, a US-based venture capital firm that guided the development of more than 50 life science companies in therapeutics, diagnostics, medical devices and personalized medicine. He held positions as Vice-President of R&D at BioAxone and as Director of Pharmacology at Neurochem where he developed neuroprotective and neuroregenerative drugs for Alzheimer’s disease and spinal cord injury. He was also Assistant Professor in Neurology at the University of California in San Francisco where he worked on neurodegenerative diseases induced by prions and was part of the Nobel Laureate Team of Stanley Prusiner, Medicine and Physiology (1997).

Patrick has been involved in many innovative life science initiatives. He is one of the cofounders of the Personalized Medicine Partnership for Cancer and was intimately involved in the creation and financing of the new Neomed Institute. In recent years, he has held numerous advisory positions with diverse organizations such as the Campus des Technologies de la Santé, Quebec Consortium for Drug Discovery, Center of Excellence for Commercialization and Research of the Montreal Neurological Institute and at Pharmacology Institute of Sherbrooke University.

Patrick holds a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Molecular Biology from Montreal University. He has also completed postdoctoral studies at the Max Planck Institute for Biophysical Chemistry in Germany.

With close to 30 years of tax experience, Michel Babeu puts his extensive expertise to use in serving SMEs and owner-managed businesses. Having himself founded and managed his own accounting firm in the 1990s, he is especially known for his in-depth understanding of the challenges facing entrepreneurs. He joined Richter in 2009 following the merger of RSM Richter and Chamberland Hodge. Michel is a tax partner in the firm.

Coming shortly

Coming shortly

Sylvain Chrétien has more than 31 years of experience in the pharmaceutical and biotechnology sector through which he has worked in various key positions. Before recently returning to his current position as President of Bioprisma Management, a pharmaceutical and biotechnology consulting firm he founded, Mr. Chrétien was previously President of Medexus Pharma Canada, a division of Medexus Pharmaceuticals Inc., a specialty pharmaceutical company with a North American commercial platform, resulting from the merger of 3 entities: Pediapharm, Medexus and Medac USA. Mr. Chrétien also acted as a member of the Board of Directors of the Public Corporation on the TSX.V and symbol MDP.

A chartered accountant, Mr. Cyr is vice-president and chief financial officer of the BTB Real Estate Investment Trust. Mr. Cyr holds an MBA in finance from HEC Montréal and was president of HEC Montréal’s alumni association, as well as chair of its board of directors.

Coming shortly

Coming shortly

Coming shortly

Coming shortly

Contact Us

General information

Espace CDPQ
3 Place Ville Marie
Suite 12350
Level L, #1.180
Montréal (Québec) H3B 0E7

Telephone: 514 340-3243
Fax: 514 340-3204


Government partners

Ministère de l’Économie et de l’Innovation

The Ministère’s mission is to support the development of Quebec’s economy, innovation and exports by ensuring, coordination and cooperation among the various economic, scientific, social and cultural fields, and in a perspective of:

  • job creation;
  • economic prosperity;
  • sustainable development.

Strategic Partners

With committed capital of $41.25M, AmorChem is focused on investing in promising life science projects originating from Québec-based universities and research centres. AmorChem’s innovative business model involves financing research-stage projects to enable them to reach pre-clinical proof-of-concept in a semi-virtual mode.

The goal of the partnership between the Québec Consortium for Drug Discovery (QCDD) and Univalor is to promote the emergence of spin-off companies and the financing of research projects originating from Univalor member establishments, with a view to developing innovative technologies and tools that facilitate the drug discovery process.

This partnership between the Centre québécois d’innovation en biotechnologie (CQIB) and Univalor concentrates on developing life sciences and health care technology businesses that are created by Univalor to commercialize technology from its university partners. The selected spin-off companies have the opportunity to establish a business relationship with the CQIB and to benefit from intensive support for starting a business, from access to consulting services, and from different sources of financing.

Anges Québec’s mission is to help its angel investors make profitable investments in innovative companies in a wide range of industries and in all regions of Quebec. To this end, the organization identifies the best entrepreneurs in innovation ready to start their commercial activities or real estate promotors developing promising new business projects while supporting angel investors believing in their success.

Subscribe to our newsletter !

Scroll to Top